Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly and Company has submitted a supplemental new drug application to the FDA seeking approval for a new indication for Cymbalta for the management of chronic pain.
Subscribe to our email newsletter
The submission is based on outcomes of clinical trials in chronic osteoarthritis pain of the knee and chronic low back pain, in addition to data from previously completed pain studies in diabetic peripheral neuropathic pain and fibromyalgia.
Cymbalta was studied in chronic pain of at least moderate severity in adults who required daily treatment for an extended period of time.